Table 2.
Baseline characteristics and outcomes of AML patients evaluable for DLT and efficacy assessments (n=13)
| Pt | Age | Prior dx |
# prior tx |
Ruxo dose |
cyto | PS | # courses |
Response/Current Status |
COD | OS (wks) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 51 | PV | 3 | 50 | complex | 2 | 2 | NR/died | PNA/DAH | 8 |
| 2 | 66 | CMML | 3 | 50 | −7 | 2 | 1 | NR/died | CVA/cerebral edema | 6 |
| 3 | 69 | MDS | 4 | 50 | del6 | 1 | 4 | NR/died | E. coli sepsis | 15 |
| 4 | 70 | PV | 3 | 100 | del6 | 2 | 1 | NR/died | unknown | 22 |
| 5 | 41 | none | 8 | 100 | Abnl11q | 1 | 1 | NR/died | PNA/DAH | 4 |
| 6 | 85 | MDS | 5 | 100 | dip | 1 | 1 | NR/died | PNA | 4 |
| 7 | 81 | Colon cancer | 3 | 200 | dip | 1 | 3 | NR/died | PNA | 12 |
| 8 | 55 | MF | 2 | 200 | complex | 1 | 1 | NR/died | unknown | 35 |
| 9 | 83 | MDS | 4 | 200 | dip | 1 | 1 | NR/died | unknown | 5 |
| 10 | 67 | ET/MF | 1 | 200 | dip | 2 | 4 | NR/died | unknown | 17 |
| 11 | 71 | ET | 1 | 200 | complex | 2 | 3 | NR/died | unknown | 13 |
| 12 | 66 | MDS | 7 | 200 | +8 | 1 | 3 | CRp/died | unknown | 12 |
| 13 | 75 | MDS | 7 | 200 | Dip | 1 | 2 | NR/alive | Alive | 16 |
Abbreviations used: NR=Non-responder, CRp=complete remission with incomplete recovery of platelet count, PNA=pneumonia, DAH=diffuse alveolar hemorrhage, CVA =cerebrovascular accident (stroke)